IN THE CLAIMS:

Claim 1 was amended herein. Claims 2-45, 47, and 51-116 are canceled after entry of this amendment without prejudice to prosecution in a continuing application Please note that all claims currently pending and under consideration in the referenced application are shown below. Please enter these claims as amended. This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1 (currently amended): An isolated protein complex comprising two proteins, the protein complex selected from the group consisting of:

(i) a complex of a first protein and a second protein;

(ii) a complex of a fragment of said first protein and said second protein;

(iii) a complex of said first protein and a fragment of said second protein; and

(iv) a complex of a fragment of said first protein and a fragment of said second protein, wherein said first and second proteins of (i)-(iv) are selected from the group consisting of:

(a) said first protein is AKT1 or a homologue at least 90% identical thereto and said second protein is selected from the group consisting of FNTA, TRPD, KIAA0728, PPL and Golgin-84, or a homologue at least 90% identical thereto; and

(b) said first protein is AKT2 or a homologue at least 90% identical thereto and said second protein is selected from the group consisting of CLIC1, AKR7A2 and TPRD or a homologue at least 90% identical thereto; ~~and~~

~~(c) said first protein is p90RSK and said second protein is selected from the group consisting of KIAA0728 and UNR.~~

Claims 2-45 (Canceled)

Claim 46 (previously presented): A method for screening for drug candidates capable of modulating the interaction of the proteins of a protein complex, the protein complex selected from the group consisting of the protein complexes of claim 1, said method comprising:

(i) combining the proteins of said protein complex in the presence of a drug to form a first complex;

(ii) combining the proteins in the absence of said drug to form a second complex;

(iii) measuring the amount of said first complex and said second complex; and

(iv) comparing the amount of said first complex with the amount of said second complex, wherein if the amount of said first complex is greater than, or less than the amount of said second complex, then the drug is a drug candidate for modulating the interaction of the proteins of said protein complex.

Claim 47 (canceled)

Claim 48 (original): The method of claim 46, wherein said complex is measured by binding with an antibody specific for said protein complexes.

Claim 49 (original): The method of claim 46, wherein if the amount of said first complex is greater than the amount of said second complex, then said drug is a drug candidate for promoting the interaction of said proteins.

Claim 50 (original): The method of claim 46, wherein if the amount of said first complex is less than the amount of said second complex, then said drug is a drug candidate for inhibiting the interaction of said proteins.

Claims 51-116 (Canceled)